Form 4: PLAYSTUDIOS General Counsel Sells Over 61,000 Shares Under Pre-Arranged Trading Plan
Insider Trading Report
Joel Agena, General Counsel of PLAYSTUDIOS, Inc., sold 61,471 shares of Class A Common Stock across three days in June 2025, as part of a pre-established Rule 10b5-1 trading plan.
Summary
- Joel Agena, General Counsel of PLAYSTUDIOS, Inc. (MYPS), sold a total of 61,471 shares of Class A Common Stock over three trading days: June 16, 17, and 18, 2025.
- These sales were executed under a Rule 10b5-1 trading plan adopted on March 12, 2025, and previously disclosed in the company's Form 10-Q filed on May 9, 2025.
- On June 16, 2025, 20,491 shares were sold at a weighted average price of $1.43, with prices ranging from $1.39 to $1.48.
- On June 17, 2025, 20,490 shares were sold at a weighted average price of $1.41, with prices ranging from $1.39 to $1.44.
- On June 18, 2025, 20,490 shares were sold at a weighted average price of $1.42, with prices ranging from $1.40 to $1.44.
- Following these transactions, Mr. Agena directly beneficially owns 259,221 shares of Class A Common Stock.
- Mr. Agena also holds various derivative securities, including 291,668 Restricted Stock Units (RSUs), 125,000 Performance Stock Units (PSUs), 233,043 stock options with exercise prices ranging from $0.90 to $1.44, and 28,040 earnout shares contingent on stock price targets of $12.50 and $15.00.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While insider sales can sometimes be viewed negatively, these were conducted under a pre-established 10b5-1 plan, which mitigates concerns about opportunistic selling based on undisclosed negative information. The insider also retains a substantial equity stake through direct shares and various derivative instruments.
Positives
- The sales were conducted under a pre-established Rule 10b5-1 trading plan, indicating a planned transaction rather than a reaction to new, undisclosed negative information.
- The reporting person retains a significant number of shares and derivative securities, including 259,221 direct shares, 291,668 RSUs, 125,000 PSUs, 233,043 stock options, and 28,040 earnout shares, indicating continued alignment with shareholder interests.
Negatives
- An insider selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake.
- The sale prices of $1.41-$1.43 are relatively low, especially when compared to the earnout share targets of $12.50 and $15.00, which could suggest a lack of immediate confidence in significant short-term price appreciation to those higher levels.
Risks
- The document itself does not detail specific company risks beyond the transaction. However, the low sale prices and the high thresholds for earnout shares ($12.50 and $15.00) highlight the significant gap between current market valuation and potential future performance targets, which could be a risk for investors expecting rapid appreciation.
Future Outlook
The document does not contain explicit forward-looking statements or guidance from the company, beyond the vesting schedules for equity awards and the conditions for earnout shares.
Industry Context
This Form 4 filing reports an individual insider's stock transactions and does not provide broader industry context or trends. It is a routine disclosure of a pre-planned sale.
Related Party Transactions
- The reported transactions are related party transactions as they involve an officer of the company (Joel Agena, General Counsel) selling shares of the issuer.
Stakeholder Impact
- Shareholders: The sale by a General Counsel, even if pre-planned, might lead to minor concerns about insider sentiment, but the pre-planned nature and retained holdings mitigate significant negative impact. The low sale prices compared to earnout targets might highlight the current valuation gap.
- Employees: No direct impact on employees is indicated.
- Customers: No direct impact on customers is indicated.
- Suppliers: No direct impact on suppliers is indicated.
- Creditors: No direct impact on creditors is indicated.
Next Steps
- Continued vesting of Restricted Stock Units on various dates through January 15, 2028.
- Determination of Performance Stock Units vesting based on achievement of pre-established performance metrics for the fiscal year ending December 31, 2025.
- Potential vesting of Earnout Shares if Class A Common Stock price targets of $12.50 and $15.00 are met by June 21, 2026.
Key Dates
| Date | Description |
|---|---|
| 09/01/2018 | Date exercisable for 46,609 stock options with an exercise price of $0.90. |
| 05/01/2020 | Date exercisable for 93,217 stock options with an exercise price of $1.01. |
| 02/01/2021 | Date of the closing of the business combination pursuant to the Agreement and Plan of Merger, which is the reference point for earnout share vesting. |
| 01/01/2023 | Date exercisable for 93,217 stock options with an exercise price of $1.44. |
| 03/11/2024 | Date 358,335 unvested Restricted Stock Units were granted to the Reporting Person. |
| 03/07/2025 | Date 166,667 unvested Restricted Stock Units and 125,000 unvested Performance Stock Units were granted to the Reporting Person. |
| 03/12/2025 | Date Rule 10b5-1 trading plan was adopted by the reporting person. |
| 05/09/2025 | Date Issuer's Quarterly Report on Form 10-Q was filed, disclosing the trading plan. |
| 05/15/2025 | Vesting date for 41,667 Restricted Stock Units (from March 7, 2025 grant) and 125,000 Restricted Stock Units (from March 11, 2024 grant). |
| 06/16/2025 | Date of earliest reported transaction (sale of 20,491 shares of Class A Common Stock). |
| 06/17/2025 | Date of reported transaction (sale of 20,490 shares of Class A Common Stock). |
| 06/18/2025 | Date of reported transaction (sale of 20,490 shares of Class A Common Stock) and signature date of the filing. |
| 09/01/2025 | Expiration date for 46,609 stock options with an exercise price of $0.90. |
| 12/31/2025 | Fiscal year end for performance metrics determination for Performance Stock Units. |
| 01/15/2026 | Vesting date for 41,667 Restricted Stock Units (from March 7, 2025 grant). |
| 05/15/2026 | Vesting date for 83,334 Restricted Stock Units (from March 11, 2024 grant). |
| 06/21/2026 | Expiration date for earnout shares, contingent on price targets. |
| 01/15/2027 | Vesting date for 41,667 Restricted Stock Units (from March 7, 2025 grant). |
| 05/01/2027 | Expiration date for 93,217 stock options with an exercise price of $1.01. |
| 05/15/2027 | Vesting date for 83,334 Restricted Stock Units (from March 11, 2024 grant). |
| 01/15/2028 | Vesting date for 41,666 Restricted Stock Units (from March 7, 2025 grant). |
| 01/01/2029 | Expiration date for 93,217 stock options with an exercise price of $1.44. |
Recommendation
holdKeywords
PLAYSTUDIOS, MYPS, SEC Form 4, insider trading, stock sale, Joel Agena, General Counsel, Rule 10b5-1, Class A Common Stock, Restricted Stock Units, Performance Stock Units, Stock Options, Earnout Shares
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.